mL, respectively. PK parameters were assessed by non-compartment and compartment models. Intervals between dosing ranged from 20 to 420 days and had little impact on intra-individual variation. DNA, extracted from peripheral blood mononuclear cells (PBMCs) of 4 volunteers, showed measurable levels (LOD~0.5 adducts/10 11 nucleotides) in two individuals 2-3 h post-dose, approximately three orders of magnitude lower than smokers or occupationally-exposed individuals. Little or no DNA binding was detectable at 48-72 h. In volunteers the allelic variants CYP1B1
Introduction
Benzo[a]pyrene (BaP), the most studied polycyclic aromatic hydrocarbon (PAH), is a high priority (8th/785) environmental chemical of concern for human exposure according to the Agency for Toxic Substances and Disease Registry (ATSDR, 2013) . In preclinical models, BaP exposure results in multiple toxicities including cardiovascular, developmental, immunological and reproductive as well as multiple cancers (International Agency for Research on Cancer (IARC) IARC, Formation of covalent DNA adducts, following exposure to BaP, has long been used as a biomarker in preclinical models (Godschalk et al., 1997; Ross et al., 1995; Zuo et al., 2014) , or in vitro and ex vivo studies with human cells, postmortem or biopsy tissue (Alexandrov et al., 2002; Lodovici et al., 1998; Monein et al., 2015; Schults et al., 2013; Shiizaki et al., 2017) and human epidemiology studies, primarily with occupationally exposed populations or smokers (Borska et al., 2014; Boysen and Hecht, 2003; Divi et al., 2002; Kriek et al., 1993; Tuominen et al., 2002) . The major adduct associated with mutation and carcinogenesis (both rodents and humans) is formed from reaction of (+)-anti-BaP-7,8-dihydrodiol-9,10-epoxide ((+)-anti-BaPDHDE), the most mutagenic of four possible enantiomers) and the N 2 position of guanine is the preferred site for adduction (Jernström and Gräslund, 1994) . In A/J mice, often used in lung cancer studies, BaP-induction of adenomas correlates with time-integrated DNA adducts (Ross et al., 1995) . In the Muta Mouse model oral administration of BaP leads to an order of DNA adduction (spleen ≥ liver > lung > glandular stomach ≥ colon > forestomach) distinct from that of target organ mutation sensitivity (colon > forestomach > spleen > glandular stomach > liver = lung) or tumor incidence (forestomach > spleen > lung) (Hakura et al., 1998a (Hakura et al., , 1998b (Hakura et al., , 1999 (Hakura et al., , 2000 . Zuo et al. (2014) enhanced the prediction of target organs by also incorporating BaP-induced alteration in gene expression. Assessment of DNA adducts in peripheral blood mononuclear cells (PBMCs), a relatively non-invasive approach, of smokers or as a result of occupational exposures yields BaP-DNA adducts in the 1-50 per 10 8 nucleotide range (Alexandrov et al., 2002; Kriek et al., 1993; Pavanello et al., 2004) . Accelerator mass spectrometry (AMS), due to its remarkable sensitivity to 14 C, is finding increasing use in study of environmental carcinogens (Enright et al., 2016; Felton and Turteltaub, 1994; Ognibene et al., 2004) . Human subjects have been dosed with [
14 C]-labeled 2-amino-3-methylimidazo [4,5-f] quinolone (IQ), 2-amino-3,8-dimethylimidazo[4,5-b] quinoxaline (MeIQx), 2-amino-3-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP), tamoxifen, aflatoxin B 1 , dibenzo [def,p] chrysene (DBC) and BaP (Brown et al., 2006; Enright et al., 2016; Hummel et al., 2018; Jubert et al., 2009; Lightfoot et al., 2000; Madeen et al., 2015 Madeen et al., , 2016 . The majority of these studies with carcinogens have assayed for target organ DNA binding (Lightfoot et al., 2000; Felton and Turteltaub, 1994) (dosing prior to surgical resection) but some have examined pharmacokinetics (Hummel et al., 2018; Madeen et al., 2015 Madeen et al., , 2016 Thomas et al., 2011) .
Materials and methods
Note: This study was conducted under FDA-IND #117175 and IRB approval #5644 from Oregon State University and LLNL-approved IRB Protocol 2017-008.
Volunteers
Subjects of both sexes, 21-65 years of age, were recruited. All subjects were white not of Hispanic origin. Exclusion criteria included women that were pregnant or could become pregnant, smoking (tobacco or other substances) in the past 3 months or living with one or more smokers, regular use of medications that affect gut motility or nutrient absorption, a history of gastrointestinal surgery or gastrointestinal disorder, current or history of kidney or liver disease, prior high-dose 14 C exposure from medical tests or occupational PAH exposure (e.g. roofers, asphalt pavers, fire-fighters, etc.). We did not recruit individuals considered to be members of vulnerable populations, including those 20 years of age or younger, pregnant women, prisoners, non-English speakers, non-literate subjects or adults lacking capacity to consent. Following receipt of a signed informed consent, volunteers were given a physical exam by the study physician and blood chemistry analysis performed (including a pregnancy test for women). The demographics of the five individuals participating in the present study are given in Table 1 . Three male and two females subjects 30-63 years of age with BMIs of 18.5-36.5 were enrolled and dosed with [ 14 C]-BaP on three separate dosings to follow a 0-72 h time course. In order to minimize the contribution of daily BaP exposure due to this study, for two weeks prior to micro-dosing of [ 14 C]-BaP and during the 72 h study, subjects were requested to refrain from consuming smoked meats or cheeses and charcoal-broiled meat. A dietary questionnaire was completed by each subject for the 3 days prior to dosing. Levels of dietary consumption of BaP were estimated using the guidelines of Dieziel et al. (2011) .
Dosing and blood collections
Subjects fasted overnight before Day 1 of each cycle. Each cycle was performed thrice with a minimum two week "washout" between cycles. The actual interval between cycles varied considerably (20-420 days) based on subject availability. A catheter was placed in an appropriate vein and a time zero blood sample taken prior to swallowing a capsule containing 46 ng (5 nCi) of [7- 14 C]-BaP (27 nCi/nmol), with water. The 
Plasma extraction and determination of [

C]-BaP eq by AMS
Aliquots of plasma (0.75 mL or 1.5 mL for metabolic profiles) from each time point were extracted within two hours after collection according to the method of Crowell et al. (2011) . The protocol is described in detail in Hummel et al. (2018) . Samples were evaporated and flame-sealed in a quartz tube containing Cu(II) and combusted to 900°C, producing CO 2 which was then transferred to a septa sealed glass tube containing Zn and Co and heated to 525°C, producing graphite on the Co catalyst. The graphite was loaded into an aluminum sample holder for AMS analysis, performed on the 250 kV single stage AMS, constructed and maintained by the Center for Accelerator Mass Spectrometry at LLNL (ratio of 14 C:C with a precision of 3% and sensitivity of 0.7 attomol 14 C per mg total carbon) . As in previous studies (Madeen et al., 2015 (Madeen et al., , 2016 Hummel et al., 2018) biochemical samples are measured 4-10 times with at least 10,000 14 C counts or for 30 s (each replicate) . Pharmacokinetic Analysis: Pharmacokinetics of total BaP equivalents (BaP and BaP metabolites, [ 14 C]-BaP eq ) were evaluated using noncompartmental and compartmental analyses. Area under the curve (AUC) values to the last measured time point and extrapolated to infinity (using last 3 time points) were calculated using the trapezoidal rule (Gibaldi and Perrier, 1982) . Mean resident times were calculated as a ratio of AUC under the 1st moment curve extrapolated to infinity to AUC extrapolated to infinity. Non-compartmental half-lives were calculated as the product of mean resident times with the natural log of two. A two-compartment pharmacokinetic model was used to evaluate the time course of [ 14 C]-BaP eq (Eqs. 1-3), where "A0", "A1", and "A2" represent the amount (fg) of [ 14 C]-BaP eq in the absorption, central, and peripheral compartments, respectively; "ka", "ke", "k12", and "k21" are first-order rate constants. The concentration of the central compartment (C1) was calculated by normalizing the amount with the volume of distribution (V1, L, Eq. 4).
Model parameters were optimized using a maximum log likelihood objective and the Nelder-Mead algorithm. Initial values were set by adjusting parameters visually. Software used to statistically analyze data was "R: A language and environment for statistical computing" Version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).
DNA extraction from PBMCs and determination of BaP eq covalent binding to DNA
Peripheral blood mononuclear cells (PBMCs) were isolated from blood of each volunteer at each time point and DNA isolated for determination of total [
14 C]-BaP eq bound using the graphite AMS assay as previously described (Felton and Turteltaub, 1994) . DNA (average yield 24 ± 8 μg/mL whole blood) was extracted with a DNA Isolation Kit for Mammalian Blood (Roche Diagnostics, Indianapolis, IN). The DNA pellet was washed twice with 100% and once with 70% ethanol prior to solubilizing in nuclease-free water for determination of the concentration and purity via a Nanodrop ND-1000 (Thermo Scientific, Wilmington, DE). Samples were prepared as 200 ng/μL solutions. Twenty μg of DNA were analyzed by graphite AMS. The limit of adduct detection (LOD) for the 20 μg DNA sample was 0.2 fg (10 fg [ 
Genotyping for CYP1B1*1 vs.*3 and GSTM1*1 vs. GSTM1*0 Alleles
CYP1B1*1 and *3 alleles were distinguished by Sanger sequencing. PCR products were amplified from PBMC DNA (extraction described above) in a 20 μL reaction containing 200 ng DNA, 250 nM forward and reverse primers, and 10 μL SsoFast™ Supermix (Bio-Rad). The product was cleaned with Exo-SAP-IT™ (Applied Biosystems) per manufacturer's instructions and sequenced at the Oregon State University Center for Genome Research and Biocomputing on an ABI 3730 capillary sequencer using ABI's Big Dye Terminator chemistry. Sequences were visualized using FinchTV v. 1.5 (Supplemental Fig. 1 ). GSTM1 nulls were determined using a conventional PCR amplification. PCR components were the same as described above using GSTM1 specific primers to detect homozygotes or heterozygotes for a GSTM1 allele. Primers for human beta globin (HBB) were used as a control in the event an individual was a GSTM1 null. See Supplemental Table 1 for a list of primer sequences. Products were visualized on 10% TBE gels (Supplemental Fig. 2 ).
UPLC-AMS analysis of [ 14 C]-BaP and metabolites extracted from human plasma
The following BaP metabolite standards were obtained from the PAH repository of the Oregon State University Superfund Research Program (http://limsweb.science.oregonstate.edu/, accessed 8-22-2018); BaP-9,10-diol, BaP-7,8-diol, BaP-1,6-quinone, BaP-3,6-quinone, BaP-6,12-quinone, BaP-7,8-dione, 3-hydroxy-BaP, 7-hydroxy-BaP, 9-hydroxy-BaP, BaP and DBC (internal standard). Resolution of BaP and metabolites was performed with a Waters Acquity H series UPLC. The column utilized was a Waters Acquity UPLC BEH C18 1.7 μm, 2.1 × 50 mm (Part # 186002350) with a guard column (part #186003981). Solvent A was HPLC-grade H 2 O with 0.3% formic acid and solvent B was HPLC grade (PEG free) acetonitrile. Initial conditions were 40% B for 2 min followed by a linear gradient to 60% B over 5 min with a hold at 60% for an addition 5 min following which solvent B was increased by a linear gradient to 80% over 10 min, and then to 100% over 5 min followed by a 3 min gradient return to 40% B. The samples were maintained at 20°C in an autosampler. The column temperature was maintained at 28°C. Five μL was the injection volume and the column was eluted at 0.25 mL/min. BaP and metabolite standards were prepared in acetonitrile and stored at −80°C until analysis. The plasma extracts of [ 14 C]-BaP and metabolites (100 μL) in ethyl acetate were evaporated (Speed Vap, vacuum only with no centrifugation) to dryness and the residue redissolved in acetonitrile and transferred to the autosample vials. BaP and metabolites (Supplemental Table 2 ) were analyzed by a Waters Acquity UPLC PDA detector. Analysis of plasma extract containing [ 14 C]-BaP and metabolites was by collection of the UPLC eluate onto a nickel moving wire (periodically indented to hold solvent) that passed through a cleaner prior to deposition of the eluate. The wire with eluate is passed through a drying oven followed by a combustion oven to convert the sample to 14 CO 2 before entering the 250 kV AMS. The 250 kV [ 14 C]-AMS detector employed has previously been validated as an analytical instrument for pharmaceutical development (Keck et al., 2010) . With respect to the moving wire interface with the UPLC and AMS we have previously established the LLOQ at 200 zmol [ 14 C] ( Thomas et al., 2011) . Thus, with a specific activity of [ 14 C]-BaP (27 nCi/nmol) and a molecular weight of 252 ng/nmol, the LLOQ is 1.2 fg. The accuracy was 1-3% with a precision (coefficient of variation) between 1 and 6% (Keck et al., 2010) . A more complete description of the system is provided by Thomas et al., (2011) and https://www.youtube.com/watch?v=oFi17Vho44k (accessed 8-22-2018).
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Pharmacokinetics of [ 14 C]-BaP eq
Pharmacokinetic parameters in plasma of volunteers were compared as a function of the interval between dosing. The relatively small difference between cycles (with the exception of 1 dose with subject BaP002) indicates little intra-individual variation in BaP pharmacokinetics, even with up to 60 weeks between runs, and variation did not correlate to days between doses (Fig. 1) . The small number of individuals analyzed does not allow for any conclusions with respect to impact of gender, age, race/ethnicity, or BMI ( 
Time course of covalent binding of [ 14 C]-BaP eq to PBMC DNA
In four of the five volunteers, PBMCs were isolated from plasma at various time points up to 72 h post-dose to assess covalent binding of [ 14 C]-BaP eq to DNA. In two volunteers, (BaP002 and BaP003), no DNA adduction was detected at any time point (Fig. 2, top panel) . With volunteers BaP004 and BaP009 a small amount of adduction is seen at 2 and 2.5 h, respectively (Fig. 2) . With the possible exception of the 24 h time point for volunteer BaP004, no DNA adduction is observed 24-72 h post-dosing consistent with previous studies with both [ 14 C]-DBC eq (Madeen et al., 2015 (Madeen et al., , 2016 (Hummel et al., 2018) . A recently developed ultrasensitive high-resolution mass spectrometric assay (Villalta et al., 2017 ) achieved a similar LOD (1 adduct/ 10 11 nucleotides) with BaP in human lung.
Time course of [ 14 C]-BaP metabolites in plasma of two volunteers
The [ 14 C]-BaP metabolite profile for volunteers BaP002 and BaP009
was assessed over the 72 h time course utilizing the moving wire UPLC-AMS system developed by the Biomedical Research group at LLNL (Thomas et al., 2011; Ognibene et al., 2015; Madeen et al., 2016 E. Madeen et al. Toxicology and Applied Pharmacology 364 (2019) [97] [98] [99] [100] [101] [102] [103] [104] [105] (M4, 7.66 min) in the region where quinones (could not distinguish between the 1,6-, 3-6-or 6,12-quinone) are seen. In the plasma extract from volunteer BaP009, M2 is also a major metabolite and is seen in plasma with a time course similar to volunteer BaP002. A second major metabolite (M5, 12.86 min) which has a C max 45 min post-dosing, with a smaller peak at 90 min, elutes with a retention time matching 3-hydroxy-BaP (Fig. 3) . Figs. 1 and 2).
CYP1B1 (*
Discussion
In the present report five volunteers, fasted overnight, were given capsules on three separate occasions with the same dose of [ 14 C]-BaP. It should be noted that (with the exception of BaP002) there was markedly low intra-individual variation in the PK profile of [
14 C]-BaP eq independent of the interval between doses. As in rodent models (Crowell et al., 2011) , BaP is fairly rapidly eliminated from plasma. We found that at doses 5-15-times lower than the estimated daily exposure to BaP in the U.S., very little parent compound was present in plasma, even at the earliest time points, perhaps indicative of extensive hepatic and/or intestinal first-pass metabolism. (Fig. 1) to UPLC-AMS (Fig. 3) , the latter is 26-33% lower than the former (based on AUC 0-72h ]-BaP was a minor component even at the earliest time points. The more rapid metabolism of BaP, compared to DBC, is consistent with in vitro studies at much higher concentrations (Crowell et al., 2014; Smith et al., 2017) whereas the rates of phase 1 and phase 2 metabolism of BaP-7,8-DHD and DBC-11,12-DHD are similar (Smith et al., 2017) .
The metabolic profile of [ 14 C]-BaP exhibited some differences and similarities in the two individuals examined. In one individual (BaP002), a BaP quinone, not seen in the profile from BaP009, was observed although the second of the two major metabolites was the same and markedly more polar, probably a dihydrodiol (possibly a tetrol for which no standard was examined). Another striking difference was the lack of formation of any phenols with BaP002 whereas 3-hydroxy-BaP was a major metabolite found in plasma from BaP009. The later eluting smaller 3-hydroxy-BaP peak in plasma may be indicative of enterohepatic recirculation.
PAHs, such as BaP and DBC, have multiple mechanisms of carcinogenesis. Metabolic activation by CYPs in the 1 family (especially CYP1B1) to bay or fjord region epoxides are rapidly hydrolyzed by epoxide hydrolase to two stereo isomers ((+/−)-BaP-7,8-DHD or (+/−)-DBC-11,12-DHD) followed by a second CYP1-epoxygenation to Table 2 Plasma pharmacokinetics of [ e One outlier of 2683 h was not used in the calculation.
E. Madeen et al. Toxicology and Applied Pharmacology 364 (2019) 97-105 the potent electrophilic anti-or cis-dihydrodiol-epoxides (4 enantiomers each of BaP-7,8-DHD-9,10-E or DBC-11,12-DHD-13,14-E). BaP readily forms covalent DNA adducts, predominantly the N 2 -(7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene-C10-yl)-2′-deoxyguanosine (N 2 -BaP-DHDE-dG) whereas DBC-11,12-DHD-13,14-E has a preference for adduction at N 6 -adenosine. Additional mechanisms of carcinogenesis involve reduction of the DHD by aldo-keto reductase (AKR) to electrophilic and redox active catechols (Penning, 2014; Quinn and Penning, 2008) . In our UPLC system the BaP-7,8-dione had a retention time of 9.34 min and was well resolved from the three quinones and phenols (we did not have a standard of the . With PAHs, one-electron oxygenations by peroxidases also produce electrophiles (Zamzow et al., 1989) . Carcinogenicity can also result from PAHdependent alteration of expression of genes important in tumor production through binding to the aryl hydrocarbon receptor (AhR) (Shimizu et al., 2000) . DBC, a six-membered PAH with both a bay-and fjord-region, is a potent carcinogen in preclinical rodent models. In the study with [ 14 C]-DBC, the major plasma metabolite observed was tentatively identified as DBC-11,12-DHD yet we found no evidence of covalent DNA adduction in PBMCs (Madeen et al., 2016) . In this study with [
14 C]-BaP, although extensive metabolism was evident, little or no covalent DNA adduction was observed 48-72 h after dosing. Two out of four volunteers examined over the 72 h time-course showed [ 14 C]-BaP DNA binding at an early time point (2 and 2.5 h for volunteers BaP004 and BaP009, respectively), which we originally believed was random noise, however, DNA from PBMCs from BaP009 gave similar results over 2 separate dosing time-courses. We are continuing to examine this issue with a planned dose-response study. Can studies such as this be useful in prediction of cancer risk from truly environmentally relevant levels of exposure to carcinogenic PAHs or other carcinogens? There are limitations to this study including sample size and a single dosage not reflective of steady-state concentrations with daily exposures. The EPA has set an oral cancer slope factor (upper bound for risk) for BaP of 1 (mg/kg-day) −1 . The lifetime risk-specific dose equating to 1 cancer in 10 6 is 1.0 × 10 −6 mg/kg-day which is approximately twice the risk if the dose used here (5.2 × 10 −7 mg/kg) were administered every day of the volunteer's lives. If we utilized covalent DNA adduction to predict cancer susceptibility Kriek et al., 1993; Lee et al., 2002) , the limited DNA adduct data we have to date would indicate a risk markedly < 1 in 10 6 . Due to extensive metabolism of [ 14 C]-BaP, observed by UPLC-AMS, the plasma C max following our single dose of 46 ng ranged from 9 to 15 fM (two volunteers). Utilizing our PBPK model (Crowell et al., 2011) , the estimated C max in liver would be 0.12-0.2 pM, over 10 6 -fold lower than the calculated K m (0.725 μM) in human liver microsomes (Crowell et al., 2014) and the IC 50 in a BaP competitive binding assay with human AhR (Flaveny et al., 2009) . Thus it would seem unlikely that BaP would impact the expression of AhR-dependent gene expression following this exposure although no alterations in the transcriptome were examined in this study. It is also useful to relate our data to studies with human cells in vitro and BaP plasma concentrations and degree of PBMC DNA adduction found in vivo with human populations. Peak plasma levels of [
14 C]-BaP in this study are > 3 orders of magnitude lower than the BaP median level of 4-19 pg/mL from a study by Pleil et al. (2010) , examining a healthy student population and about 30,000 fold lower than concentrations found to have no adverse impact on Hepa1c1c7 hepatocytes (Madureira et al., 2014) . The levels of BaP-DNA adducts in PBMCs from occupationally exposed workers have been reported to be 1-10 adducts per 10 8 nucleotides (Boysen and Hecht, 2003; Carstensen et al., 1999; Divi et al., 2002; Pavanello et al., 2005) . The levels of covalent DNA adduction in PBMCs from volunteers in our study were at least 3 orders of magnitude lower, again indicating little to no measurable risk from this exposure. Somewhat surprisingly, history of exposure (smoking, occupational) has been reported as not significantly elevating BaP-DHDE-DNA adducts in PBMCs or other tissues (Boysen and Hecht, 2003; Carstensen et al., 1999) . Other studies report modestly higher levels in smoker's compared to non-or ex-smokers (Lodovici et al., 1998; Villalta et al., 2017) Examination of 10 human lung biopsy samples by Monein et al. (2015) found no detectable (LOD 1-3 adducts per 10 8 nucleotides) BaP-DHDE-dG adducts. Recent advances in methodology, leading to increased specificity and sensitivity for assaying BaP-DNA adducts, have improved (LOD of~1 adduct in 10 11 nucleotides). Villalta et al. (2017) reported levels of (predominantly 7R,8S,9S,10R) BaP-DHDE-N 2 -dG adducts in lung biopsies from smokers and non-smokers as 3.1 and 1.3 adducts per 10 11 nucleotides, respectively.
Another potential use of UPLC-AMS technology, if expanded, is identification of resistant and susceptible individuals. Measures of BaP-DNA adducts in humans is likely driven by gene-environment interactions. A number of studies have documented enhanced cancer susceptibility for individuals expressing the GSTM1*0 (null) allele (approximately 50% in Caucasians) (Alexandrov et al., 2002; Boysen and Hecht, 2003; Pavanello et al., 2004; Pavanello et al., 2005; Rojas et al., 1998; Wenzlaff et al., 2005a) . As all volunteers examined for [ 14 C]-BaP DNA adduction in PBMCs were GSTM1 nulls, this study could not examine the impact of GSTM1 expression.
Studies suggest individuals expressing the CYP1B1*3 allelic variant (about 39% in Caucasians) have an enhanced risk of some cancers including lung (Shah et al., 2008; Wenzlaff et al., 2005b; Xu et al., 2012) , ovarian (Goodman et al., 2001) , and head and neck cancer in smokers (Thier et al., 2002) , but not for colorectal cancer (Xie et al., 2012 ). An inverse relationship is seen for prostate cancer (Beuten et al., 2008) . Individuals with both CYP1B1*3 (or CYP1A1*2, not examined in this study) and GSTM1*0 alleles have an enhanced lung cancer risk compared to either alone (Alexandrov et al., 2002; Shah et al., 2008) . The CYP1B1.3 (L432 V) enzyme is expressed at about 50% the level of CYP1B1.1, is less responsive to induction by BaP (human lymphocytes) and exhibits a 25% lower K cat for BaP epoxygenation to the 7,8-DHD (Aklillu et al., 2005; Helmig et al., 2014) . These observations would seem to be inconsistent with an enhanced lung cancer risk if CYP1B1-dependent formation of BaP-7,8-DHD-9,10-E were critical. The two individuals examined for [
14 C]-BaP metabolic profiles in plasma were homozygous for either CYP1B1*1 or CYP1B1*3. The extent of metabolism and profile of metabolites was distinct suggesting further genotype-dependent studies are warranted. The same could be said for the GSTM1 allelic variant. A limitation of this study was failure to positively identify BaP metabolites. Work is in progress at LLNL to send the UPLC sample (spiked with unlabeled metabolites standards) elute through a splitter, a UV/VIS scanning detector and conventional MS/MS for positive identification of peaks with the same retention time as the AMS 14 C peaks.
These studies complement and expand PK determinants of PAHs such as BaP and DBC (Crowell et al., 2014) and their metabolites (Smith Blood was collected from volunteers BaP002 and BaP009 at intervals from 0 to 72 h and plasma isolated and extracted with ethyl acetate. The extract was taken up in acetonitrile and [ 14 C]-BaP and metabolites resolved utilizing UPLC interfaced via a "moving wire" into a 250 kV AMS. The UPLC conditions and operation of the "moving wire" interface were as described in Materials and Methods. Metabolites 1-3 (M1 , M2 and M3 ) eluted early in the gradient (Supplemental Table 2 ) and are possibly dihydrodiols or tetrols. The metabolite designated "quinone" (M4 ) eluted at 7.66 min. At this time we cannot, with confidence, designate this peak as either the 1,6-, 3,6-or 6,12-quinone of et al., 2017) in vitro with human liver microsomes of BaP at concentrations at least 6 orders of magnitude greater than the C max in liver (based on the PBPK model from Crowell et al., 2011) . Such an approach is consistent with the philosophy of "the best model for humans is humans".
